early development. Although ES cells are an attractive source for the generation of cardiomyocytes, 9 a lack of reliable selective differentiation methods has impeded the clinical application of ES cell technology for cardiomyocyte production. The potential of ES cells to form cardiomyocytes was realized when embryoid bodies (EB), a pseudoembryo with a central cavity formed by culturing ES cells in a suspended state, were shown to produce cardiomyocytes without specific induction of differentiation. It has subsequently been reported that cardiomyocytes can be specifically induced to differentiate from human ES cells. 10 Although various factors are known to induce the differentiation of cardiomyocytes from EB, including bone morphogentic protein (BMP)-2, 11 fibroblast growth factor (FGF), 12 insulin-like growth factor (IGF)-1, 13 H2O2, 14 ascorbic acid, 15 and retinoic acid, 16 the level of cardiomyocyte production is not sufficient.
Several signals, including BMP, 19, 20 Wnt 21 and FGF, 22 are involved in heart development, but there is little evidence available on the signals that mediate cardiomyocyte differentiation from ES cells, although it is known that the process may involve Wnt and Notch-mediated signals. 17, 18 To investigate the signals underlying cardiomyocyte differentiation my group have developed an effective protocol for differentiating cardiomyocytes from ES cells. Although BMP signaling plays a crucial role in mesodermal induction and cardiac development, 19, 20 treatment of ES cells with BMP-2 or BMP-4 does not augment or suppress cardiomyocyte induction. In the vertebrate nervous system, Noggin and other BMP-inhibitors (Chordin and Follistatin) are involved in neural differentiation in a context-dependent fashion. 23, 24 It is possible that BMP antagonists are also involved in cardiomyocyte induction. Whole-mount in situ hybridization with probes for various BMP antagonists on mouse embryos at different stages of gastrulation has been performed and the BMP antagonist, Noggin, was transiently but strongly expressed in the heart-forming area (Fig 1) . 25 It was clearly expressed at the cardiac crescent at E7.5 and the late crescent stage at E8.0, but was barely detectable inCirculation Journal Vol.69, December 2005 layers derived from the primary heart field. This marked difference in the time course of Noggin expression between the heart-forming region and notochord suggests that transient expression of Noggin has a function in cardiomyocyte differentiation.
Murine ES cells in suspension culture were stimulated with Noggin under various experimental conditions (Fig 2) . 25 ES cell cultures were exposed to Noggin before or after EB formation to model the transient and strong expression of Noggin at the early gastrulation stage. Removal of leukocyte inhibitory factor (LIF) and the addition of Noggin before or after EB formation did not increase the incidence of spontaneously beating EB. By comparison, removal of LIF and addition of Noggin at days -3 and 0 from EB formation, slightly but significantly increased the incidence of beating EB, suggesting that the optimal timing for Noggin might be both prior to and after EB formation. Noggin was then added at days -3, 0, +1, +2 or +3, and LIF prior to EB formation. Adding Noggin at day 0 slightly increased the incidence of beating EB, but gradually decreased it at the other time points. Based on these results, Noggin was administered at days -3 and 0 from EB formation, and this led to a marked increase in the incidence of beating EB to 95.3% at 10 days, and continued growth of EB to day 14. Two independent ES cell lines behaved consistently and the optimal concentration of Noggin was 150 ng/ml. These results suggest that the induction of cardiomyocytes by Noggin is restricted to the period from 3 days prior to 1 day after EB formation, and that the ES cells must initially be undifferentiated.
To demonstrate specific inhibition of the BMP pathway by Noggin the ES cells were exposed to various concentrations of BMP-2 at day 0. The results confirmed that even low doses of BMP-2 strongly inhibited Noggin-dependent cardiomyocyte induction. To confirm whether inhibition of BMP signaling early in ES cell differentiation can accelerate cardiomyocyte induction, ES cells were also exposed to soluble BMP receptor-1A (BMPR-1A), or another BMP antagonist, Chordin. Both BMPR-1A and Chordin augmented the incidence of onset of beating in individual EBs. By comparison, administration of various growth factors, including IGF-1, FGF-2, and BMP-2, under the same conditions did not boost cardiomyocyte induction. These results suggest that inhibition of BMP signaling in undifferentiated ES cells or in the early phase of ES cell differentiation is crucial for cardiomyocyte differentiation.
Cardiomyocyte induction by Noggin was quantified by immunostaining for cardiac-specific proteins and the results were examined by confocal LASER microscopy. Most cells in the Noggin-treated EBs stained positive for myosin heavy chain (MHC), myosin light chain (MLC), atrial natriuretic peptide (ANP), cardiac troponin I, and sarcomeric actinin (Fig 3) . 25 In contrast, these cardiac proteins were markedly lower in the control or in EBs treated with Noggin under different conditions. Synchronous beating of EBs was observed and isolated cells expressed many cardiac markers and displayed myocyte characteristics. By day 10, EBs had attached to gelatin-coated dishes, stained with anti-MHC antibodies and contained a 100-fold increase in the number of cardiomyocytes.
Accumulating evidence implicates BMP signaling in cardiac differentiation. In chick embryos, exposure of explant cultures to BMP-2 or BMP-4 induces full cardiac differentiation in stage 5 to 7 anterior medial mesoderm, a tissue that is normally not cardiogenic. 28, 29 By comparison, both BMP-2 and BMP-4 inhibit cardiomyogenesis prior to stage 3 or during the early stages of gastrulation. 30 Although BMPs are expressed in lateral plate mesoderm, including the anterior lateral plate, 31 stimulation of ES cells by BMP-2 or BMP-4 does not augment cardiomyocyte differentiation. Together, these results suggest that BMPs play multiple roles in mesodermal induction and specific organ differentiation, and that their temporal and spatial expression is critical in cardiomyocyte induction. 30 If the action of BMP in cardiomyocyte induction is analogous to its context-dependent differential action, the action of BMPs in cardiomyocyte induction may be explained by the local action of Noggin and other BMP inhibitors. Noggin is temporally but strongly expressed at the anterolateral plate in mouse embryos at E7.0-E8.0, and plays a critical role in cardiomyocyte induction. The restricted and highly effective window of Noggin's inductive action for cardiomyocyte differentiation from ES cells matches exactly the conditions during normal developmental of the heart in E7.0-E8.0 embryos. Those results suggest that BMP signaling is essential for at least 2 steps in the cardiomyocyte induction process: mesodermal induction 32 and cardiomyocyte differentiation. 19, 20 Between these steps, it is proposed that a transient block of intrinsic BMP signaling is essential for the determination of cardiomyogenic (CMG) differentiation.
The temporal and spatial expression of Noggin and BMP-2 is important for the in vivo and in vitro differentiation of cardiomyocytes, in addition to the central nervous system. The protocol used by my group is predicted to advance the use of ES cell-derived cardiomyocytes in regenerative therapy.
Bone Marrow Mesenchymal Stem Cells as a Source of Cardiomyocytes
Hematopoietic stem cells account for more than 99% of the bone marrow, whereas mesenchymal stem cells are present at low levels. Mesenchymal cells have the capacity to differentiate into osteoblasts, chondrocytes, and adipocytes, 33, 34 and it has also been reported that they differentiate into skeletal muscle cells, cardiomyocytes, 3, 4 and neurons. 35 The possibility that marrow stromal cells might also differentiate into cardiomyocytes lead to screening for marrow 
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stromal cells that began to spontaneously beat after exposure to 5-azacytidine, a cytosine analog capable of altering expression of certain genes that regulate differentiation. Adult marrow stromal cells were used to isolate a cell line, known as CMG that differentiates into cardiomyocytes. The use of adult tissue as the source of cardiomyocytes makes this system particularly suitable for the development of cardiomyocytes for transplantation. Clonal analysis led to the isolation of several clones that could differentiate into cardiomyocytes and show spontaneous beating. These experiments were reproducible, but the percentage of differentiated cardiomyocytes differed between the clones.
Phase-contrast microscopy revealed that CMG cells displayed a fibroblast-like morphology before 5-azacytidine treatment (0 week), a phenotype that was retained through repeated subculture under non-stimulating conditions. Within 1 week of 5-azacytidine treatment the morphology of the cells gradually changed, with approximately 30% of the cells gradually increasing in size to form a ball-like appearance, or lengthening in 1 direction, forming a stick-like shape. Adjoining cells connected after 2 weeks and formed myotube-like structures after 3 weeks (Fig 4) . The differentiated CMG myotubes did not de-differentiate and maintained the cardiomyocyte phenotype and beat vigorously for at least 8 weeks after the final 5-azacytidine treatment. Most of the other non-myocytes resembled adipocytes.
Transmission electron microscopy revealed that differentiated CMG myotubes had the typical striation and palestaining pattern of sarcomeres with nuclei positioned in the center of the cell, not beneath the sarcolemma. Membranebound dense secretory granules measuring 70-130 nm in diameter were the most conspicuous feature of differentiated CMG cells. These granules, thought to be atrial granules, tended to concentrate within the juxtanuclear cytoplasm, with small numbers also located near the sarcolemma. These findings suggest that CMG cells have an ultrastructure consistent with cardiomyocytes.
An electrophysiological study was performed on differ- entiated CMG cells 2-5 weeks after 5-azacytidine treatment and 2 types of morphological action potentials were distinguished: sinus node-like potentials (Fig 5A) , and ventricular myocyte-like potentials (Fig 5B) . The sinus node-like action potential showed a relative shallow resting membrane potential with late diastolic slow depolarization, similar to the potential of a pacemaker. Peak and dome-like morphologies were observed in ventricular myocyte-like cells. A cardiomyocyte-like action potential recorded from these spontaneous beating cells had the following properties: relatively long action potential duration or plateau, relatively shallow resting membrane potential, and a pacemaker-like late diastolic slow depolarization. Three weeks following azacytidine treatment all action potentials recorded for CMG cells revealed a sinus nodelike action potential. It was not until 4 weeks following azacytidine treatment that ventricular myocyte-like action potentials were initially recorded then found to gradually increase. It is possible that the level of ventricular myocytelike action potentials at 5 weeks was underestimated. Most of the action potentials recorded from differentiated CMG myotubes revealed a ventricular myocyte-like appearance, but were difficult to record. Furthermore, the glass microelectrode was frequently damaged, because the spontaneous contraction of the differentiated myotube at 5 weeks was too large.
Differentiated CMG myotubes expressed both ANP and brain natriuretic peptide (BNP) genes. Table 2 is a summary of the expression of cardiac contractile proteins such as -and -MHC, -cardiac and -skeletal actin genes. Both -and -MHC expression could be detected by reverse transcriptase-polymerase chain reaction in differentiated CMG cells, but -MHC expression was overwhelmingly stronger than that of -MHC. CMG cells expressed both -cardiac and -skeletal actin. Northern blot analysis revealed that the -skeletal actin gene was expressed at markedly higher levels than the -cardiac actin gene in CMG cells. Interestingly, CMG cells expressed MLC-2v, but not -2a.
A number of the characteristics of the CMG cell lines support the cardiomyocyte nature of these cells, including expression of the cardiomyocyte-specific genes ANP, BNP, GATA4 and Nkx2.5. In the ventricular muscle of small mammals there is a developmental switch from expression of -MHC, which is the predominant fetal form, to that of -MHC around the time of birth. There is also a developmental switch from the expression of -skeletal actin, which is the predominant fetal and neonatal form, to that of -cardiac actin, the predominant adult form. Differentiated CMG cells express mainly -MHC and -skeletal actin.
Expressions of -MHC and -cardiac actin were detected, but at low levels. MLC-2 genes are expressed specifically in the heart chamber; MLC-2v is expressed specifically in ventricular cells, and MLC-2a is expressed specifically in atrial cells. Differentiated CMG cells express MLC-2v, but not -2a. These results suggest that differentiated CMG cells have a fetal ventricular cardiomyocyte phenotype. Although little is known about the induction of the specific pathways of ES differentiation, there are reports of induction of ES cells into cardiomyocytes in vivo 36 and during coculture with cardiomyocytes. 37 An advantage of deriving cardiomyocytes from bone marrow mesenchymal stem cells is that a patient's own cells can be used, thereby overcoming donor rejection problems. A drawback is that, although they appear to self-replicate throughout life in vivo, the number of passages in vitro is limited and at pres- ent it is not possible to culture bone marrow mesenchymal stem cells in large quantities. Cardiomyocytes that differentiate from bone marrow mesenchymal stem cells initially assume the phenotype of embryonic ventricular myocardium, but they gradually mature and eventually exhibit adult-type gene expression. 3, 4 They also express functioning sympathetic and parasympathetic nerve receptors, consistent with cardiomyocytes in vivo. 38 
Cardiac-Specific Stem Cells
C-kit-positive or Sca-1 (stem cell antigen-1)-positive cells derived from heart tissue are capable of differentiating into cardiomyocytes. 5, 6 These cells are thought to be heartspecific stem cells and to differentiate into cardiomyocytes, smooth muscle cells, and vascular endothelial cells. C-kitpositive and Sca-1-positive cells not only have different characteristics, their capacity to differentiate also differs. These cells have the ability to proliferate to some extent in vitro, and they are regarded as a useful tool for regenerating cardiomyocytes. The C-kit antigen is a cytokine stem-cellfactor receptor also present in humans. Sca-1, on the other hand, is a mouse-specific antigen, and humans do not possess any corresponding antigen, making it difficult to apply this marker to humans. The rarity of cardiac-specific stem cells makes them difficult to isolate from biopsy specimens and poses a problem for their future clinical application.
A side population (SP) of stem cells in the heart that did not express MHC and rapidly decreased from 4 days after birth was recently characterized. 39 Fluorescence-activated cell sorter (FACS) analysis revealed the following marker profile: Ter119 -, CD45 -, CD13 -, CD11b -, CD29 + , CD44 + , c-kit low , CD34 low , CD49e -/low , CD49e low , flk-1 -~low and Sca-1 -~low . Less than 1% of the cardiac SP cells formed floating spheroid colonies upon clonal expansion in serumfree media containing FGF-2 and epidermal growth factor. Immediately after dissociation cells from these spheroid colonies expressed markers of neural precursor cells, including nestin, musashi-1 and the p75 nerve growth factor receptor. After 14 days in the presence of media containing 0.5% serum, they ceased to express nestin or musashi-1 and some of the cells expressed the neural differentiation markers MAP-2, peripherin, Neu N, Hu and P0. Another cell type expressed the cardiac-specific genes Nkx2.5, GATA4, MEF2C, ANP, Cav1.2 and -skeletal actin, and a few showed spontaneous beating (Fig 6) . These cells displayed a sinus node-like action potential. Other cells expressed GFAP or calponin and -smooth muscle actin, indicating glial and smooth muscle differentiation. These results suggest that the cardiosphere-forming population of cardiac SP cells are multipotent with the capacity to differentiate into neurons, glial cells, smooth muscle cells, and cardiomyocytes, and appear to have neural crest-like characteristics.
The neural crest-like characteristics of the cardiosphereforming population of cardiac SP cells was investigated in vivo by transplanting the cells to the neural crest of the chick embryo. These cells were found to migrate with hostderived neural crest cells and contribute to cells of the developing peripheral nervous system, such as the dorsal root ganglion and the ventral spinal nerve (Fig 7) . They also entered the lateral migration pathway, normally taken by ectomesenchymal cells that are neural crest-derived melanocyte precursors. When transplanted directly into the lateral migration pathway, the cardiosphere-forming population of cardiac SP cells successfully entered the outflow tract and conotruncus of the developing heart. Some of these cells expressed the neuronal marker Hu, and fewer expressed the glial marker GFAP. This analysis also revealed a population of these cells that contributed to major blood vessels and expressed smooth muscle actin. The contribution of the cardiosphere-forming population of cardiac SP cells to the neural crest-derived tissues in the chick embryo is consistent with the neural crest stem cell characteristics displayed by these cells.
The contribution of neural crest-derived cells to the cardiac multipotential stem cell population was investigated.
For analysis of the neural crest cell lineage, Yamauchi et al crossed P0-Cre transgenic mice with CAG-CAT-Z indicator transgenic mice, which carry a LacZ gene downstream of a chicken-actin promoter and a "stuffer" fragment flanked by 2 loxP sequences. 40 In 3 different transgenic lines lacZ expression was observed in tissues derived from neural crest cells, including spinal dorsal root ganglia, the sympathetic nervous system, the enteric nervous system, and ventral craniofacial mesenchyme at stages later in development than E9.0.
Trangenic mice carrying the P0-Cre recombinase and CAG-CAT-EGFP transgenes showed EGFP expression in tissues derived from neural crest cells, including spinal dorsal root ganglia, the sympathetic nervous system, the enteric nervous system, and ventral craniofacial mesenchyme. EGFP + cells were concentrated at the outflow tract between aorta and pulmonary artery, and aortic valves. They were also observed at the intramuscular and subepicardial layer of both ventricles, including the intraventricular septum, free wall and apex (Fig 8) , and the atrial wall. Triple immunostaining of the E17.5 heart showed a lack of staining of Fig 2) transplanted into adult mice hearts with a syringe. This experiment confirms that transplanted cardiomyocytes stably reside in the heart and can survive for a long time. Once injected the regenerated cardiomyocytes diffuse into the heart-like islands then closely adhere to surrounding cardiomyocytes and assume the form of mature cardiomyocytes that have the appearance of short strips of paper. 
Cardiomyocyte Transplantation
The concept of cardiomyocyte transplantation has been advocated since the late 1990s. 41, 41 Fetal or neonatal rat cardiomyocytes have been successfully transplanted into the hearts of adult rats and transplanted cells are viable within the heart for relatively long periods, forming gap junctions with surrounding recipient cells. Prior to the transplantation of pluripotent ES cell-derived cardiomyocytes into the heart, undifferentiated cells, and cells that have differentiated into other cell types, must be eliminated. Methods that use a cell sorter or drug-resistant genes to collect ES cellderived cardiomyocytes have been reported. [42] [43] [44] [45] These include methods that specifically label cardiomyocytes by introducing into ES cells, for example, green fluorescent protein (GFP) with a cardiomyocyte-specific promoter. In a previous study GFP was placed under the control of the myosin light-chain gene promoter and introduced into bone marrow mesenchymal stem cells. 46 Fig 9 shows that when these cells are induced to differentiate, only cardiomyocytes produce the GFP signal and can be collected to a purity of more than 99% with a FACS cell sorter. When these cells were transplanted using a syringe into the hearts of syngeneic mice they moved into the gaps between recipient cardiomyocytes (Fig 10) , became connected to surrounding cells via gap junctions, and resided stably in the heart for a long period of time. 46 This result shows the potential of regenerated cardiomyocytes as an alternative to fetal or neonatal cardiomyocytes for transplantation.
Although transplanting cells with a syringe is a simple technique, the disadvantages of this method that preclude its clinical application include the inability to transplant large numbers of cells and the low viability of transplanted cells. To improve the clinical applicability of cardiomyocyte transplantation technology Okano and coworkers produced temperature-sensitive resin coated culture dishes.
The surface of these dishes becomes hydrophilic when the temperature is lowered, so cultured cardiomyocytes can be peeled off in sheets. 48, 48 Using this approach, another method of producing cardiomyocyte sheets (Fig 11) was developed in my laboratory. 50 This new method uses poly- merized fibrin (fibrin glue) normally used in surgical operations. A thin fibrin polymer membrane on the surface of the culture dish is generated by reacting fixed concentrations of fibrinogen and thrombin. When cardiomyocytes are cultured on these dishes, they secrete a variety of endogenous proteases that break down the fibrin polymer membrane in approximately 3 days, making it possible to obtain cardiomyocytes in sheets. After 7 days of culture the fibrin is completely removed. Transplantation of the cardiomyocyte sheets is characterized by good cell viability and residence rates (Fig 12) . Most studies report that less than 10% of cardiomyocytes transplanted using a syringe reside stably in the heart, whereas few cells are lost after transplantation in which the cardiomyocyte sheets are transplanted subcutaneously. A further advantage of using cardiomyocyte sheets is that they can be layered to varying tissue thicknesses. These findings support myocardial sheet formation as an important tool in future cell transplantation technology. The efficient clinical application of this technique requires progress in the stimulation of vascularization. Although transplantation is followed by the formation of a microvascular network, large blood vessels do not form.
Myocardial Regeneration From Stem Cells in Adults
Research thus far has demonstrated that bone marrow stem cells differentiate into cardiomyocytes in vitro, but it is unknown if they migrate into the heart and differentiate into cardiomyocytes in vivo. 51 The pluripotency of hematopoietic stem cells and cell fusion by pluripotent stem cells have been investigated over the past 2 years. [52] [53] [54] There is confusion in the literature over the mechanism of in vivo repair by bone marrow cells. For this reason an analysis using an in vivo murine bone marrow transplantation model was performed to verify the formation of cardiomyocytes by any of the cells in bone marrow (hematopoietic stem cells or mesenchymal stem cells). 55 In this analysis GFPmarked hematopoietic and mesenchymal stem cells were transplanted separately into allogeneic mice exposed to a lethal dose of radiation. single hematopoietic stem cells were then harvested from GFP transgenic mice by FACS, using a technique called the KSL-SP method, and transplanted together with radioprotective cells responsible for hematopoiesis that were not labeled with GFP. In addition, mesenchymal stem cells were labeled so that they would express GFP when differentiated into cardiomyocytes. Transplantation was performed using intra-bone marrow bone marrow transplantation. This method was chosen to avoid the possibility of the transplanted mesenchymal stem cells, which are larger in diameter than hematopoietic stem cells, of becoming trapped in the lungs and other tissues. Myocardial infarction was induced in the mice transplanted with hematopoietic or mesenchymal stem cells, and their hearts were analyzed 2 months later. In mice transplanted with hematopoietic stem cells, GFP-positive cells were rare and appeared at the same frequency as previously reported for cell fusion. By comparison, the mice transplanted with mesenchymal stem cells showed actinin-staining GFPpositive cells at the infarct foci. These results suggest that mesenchymal stem cells are mobilized from the bone marrow when there is an injury associated with necrosis of myocardial tissue, such as in myocardial infarction, and that mesenchymal stem cells are capable of differentiating into cardiomyocytes at the infarct foci. The cytokine granulocyte-colony stimulating factor (G-CSF) was administered at the time when the stem cells are mobilized from bone marrow, because there was a large difference in the number of regenerated cardiomyocytes between the control group and the G-CSF group. G-CSF was demonstrated to not only mobilize hematopoietic stem cells in the blood stream, as previously known, but to have the capacity to mobilize mesenchymal stem cells (Fig 13) .
Although G-CSF is used clinically to some extent, evaluations are yet to be concluded. 56, 57 Furthermore, it is unclear if mesenchymal stem cells are mobilized in humans to the same extent as in mice and whether they have the clinical potential for regeneration of heart damage following myocardial infarction. Further studies are necessary to elucidate the molecular mechanism of action of G-CSF before its clinical potential can be fully realized.
Conclusion
The concept of "myocardial regeneration therapy for heart failure" is very appealing, but it must be founded on solid basic research and should be evaluated objectively. Stem cell research has proceeded at a rapid pace, and it may soon become possible to produce large numbers of cardiomyocytes from ES cells, or mesenchymal stem cells, or both. It is also likely that cytokine therapy will be performed clinically in the near future. Examination of the present state of affairs in transplantation research is a reminder that deeper understanding is needed.
